visualant is a public company whose shares trade under the stock symbol, vsul. the visualant spectral pattern matching™ technology directs structured light onto a substance, through a liquid/gas, or off a surface, to capture a unique chromaid™. when matched against existing databases, a chromaid can be used to identify, detect, or diagnosis markers invisible to the human eye. chromaid scanhead modules can be integrated into a variety of mobile or fixed-mount form factors. the patented technology is disruptive, making it possible to effectively conduct analyses in the field that could only previously be performed by large and expensive lab–based tests.
Company profile
Ticker
KNW
Exchange
Website
CEO
Phillip Bosua
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CIGAR KING CORP, STARBERRYS CORP, VISUALANT INC, Visualant, INC
SEC CIK
Corporate docs
Subsidiaries
Name: Particle, Inc. • Percent Ownership by Registrant: 100.0% by Know Labs, Inc. ...
IRS number
911948357
KNW stock data
Latest filings (excl ownership)
10-Q
2024 Q2
Quarterly report
15 May 24
EFFECT
Notice of effectiveness
17 Apr 24
424B3
Prospectus supplement
12 Apr 24
S-1/A
IPO registration (amended)
9 Apr 24
S-1
IPO registration
28 Mar 24
424B5
Prospectus supplement for primary offering
20 Mar 24
8-K
Entry into a Material Definitive Agreement
20 Mar 24
8-K/A
Entry into a Material Definitive Agreement
6 Mar 24
8-K
Know Labs’ Non-Invasive Glucose Monitor Achieves 11.1% MARD in Latest Clinical Research Study
6 Mar 24
8-K
Know Labs Secures U.S. $12 Million Funding for Company’s Further Execution
29 Feb 24
Latest ownership filings
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Sep 23 | Sep 22 | Sep 21 | Sep 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 4.71 mm | 4.71 mm | 4.71 mm | 4.71 mm | 4.71 mm | 4.71 mm |
Cash burn (monthly) | 37.26 k | 126.36 k | 1.80 mm | 1.29 mm | 1.22 mm | 921.75 k |
Cash used (since last report) | 80.85 k | 274.18 k | 3.90 mm | 2.79 mm | 2.64 mm | 2.00 mm |
Cash remaining | 4.63 mm | 4.44 mm | 805.72 k | 1.92 mm | 2.07 mm | 2.71 mm |
Runway (months of cash) | 124.2 | 35.1 | 0.4 | 1.5 | 1.7 | 2.9 |
Institutional ownership, Q1 2024
1.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 9 |
Opened positions | 9 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 717.08 mm |
Total shares | 1.14 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Callan Capital | 370.00 k | $233.10 mm |
Fulcrum Capital | 313.34 k | $197.40 mm |
PFG Investments | 179.98 k | $113.39 mm |
Signal Advisors Wealth | 95.79 k | $60.35 mm |
Foguth Wealth Management | 95.79 k | $60.35 mm |
LGL Partners | 42.22 k | $26.60 mm |
Patriot Financial Group Insurance Agency | 41.00 k | $25.83 mm |
MCF Advisors | 100.00 | $63.00 k |
YHB Investment Advisors | 5.00 | $3.00 k |
Proequities | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
24 May 24 | Jon Pepper | Common Stock | Gift | Dispose G | No | No | 0 | 14,000 | 0.00 | 514,000 |
8 Feb 24 | John E Cronin | Common Stock | Grant | Acquire A | No | No | 0.49 | 16,164 | 7.92 k | 16,164 |
8 Feb 24 | John E Cronin | Option to Purchase Common Stock Common Stock | Grant | Acquire A | No | No | 0.49 | 290,411 | 142.30 k | 290,411 |
8 Feb 24 | Timothy M Londergan | Common Stock | Grant | Acquire A | No | No | 0.49 | 16,164 | 7.92 k | 17,164 |
8 Feb 24 | Timothy M Londergan | Option to Purchase Common Stock Common Stock | Grant | Acquire A | No | No | 0.49 | 290,411 | 142.30 k | 290,411 |
8 Feb 24 | Larry K Ellingson | Common Stock | Grant | Acquire A | No | No | 0.49 | 16,164 | 7.92 k | 16,164 |
8 Feb 24 | Larry K Ellingson | Option to Purchase Common Stock Common Stock | Grant | Acquire A | No | No | 0.49 | 290,411 | 142.30 k | 290,411 |
8 Feb 24 | Jon Pepper | Common Stock | Grant | Acquire A | No | No | 0.49 | 100,000 | 49.00 k | 528,000 |
8 Feb 24 | Jon Pepper | Option to Purchase Common Stock Common Stock | Grant | Acquire A | No | No | 0.49 | 500,000 | 245.00 k | 500,000 |
News
Benchmark Reiterates Speculative Buy on Know Labs, Maintains $1 Price Target
29 May 24
Know Labs Q2 2024 GAAP EPS $(0.07) Misses $(0.05) Estimate
15 May 24
Know Labs To Present Clinical Research At 2024 American Association Of Clinical Endocrinology Annual Meeting
9 May 24
Benchmark Initiates Coverage On Know Labs with Speculative Buy Rating, Announces Price Target of $1
8 Apr 24
Press releases
Know Labs, Inc. Reports Second Quarter FY 2024 Results
15 May 24
Know Labs to Present Clinical Research at the 2024 American Association of Clinical Endocrinology Annual Meeting
9 May 24
Know Labs, Inc. to Host Review of Second Quarter Fiscal Year 2024 Results on May 15, 2024
8 May 24
Know Labs to Present Clinical Research at the 2024 American Physiology Summit
5 Apr 24